**
In response to a concerning rise in meningitis B (MenB) cases among young people in Kent, public health officials and bereaved families are advocating for the expansion of the MenB vaccination programme to include teenagers. The recent outbreak has seen two fatalities and numerous hospitalisations, raising critical questions about the current vaccination strategy and highlighting gaps in awareness regarding meningitis protections.
The Current Vaccination Landscape
Since 2015, infants in the UK have been routinely offered the MenB vaccine, yet teenagers and university students have missed out due to its unavailability at the time of their births. The absence of a comprehensive catch-up campaign has left many vulnerable, prompting parents to seek private vaccinations, often at significant financial cost. The MenACWY vaccine, which protects against other strains of meningitis, is currently the only vaccine offered to teenagers, leaving a notable gap in protection against the MenB strain.
The recent surge in MenB cases has prompted a targeted vaccination initiative for students living at the University of Kent’s Canterbury Campus Halls of Residence, with further assessments planned by the UK Health Security Agency (UKHSA) to evaluate the need for broader vaccination efforts.
An Urgent Reassessment
Health Secretary Wes Streeting has signalled a willingness to revisit the eligibility criteria for meningitis vaccines in light of the current outbreak. In Parliament, he emphasised the need to follow expert independent advice while urging for a review of the vaccination strategy. “I will be asking them to re-examine eligibility for meningitis vaccines,” he stated, acknowledging the need for a nuanced approach given the severity of the situation.
Tragically, the outbreak has deeply affected families, such as that of Meg Draper, a university student who lost her life to MenB in October 2025. Her parents expressed their devastation and disappointment over the lack of communication regarding the limitations of the existing vaccination programme, which they believed provided broader protection than it does. “We assumed that Megan had had a meningitis vaccination… it was after we knew what strain she had that we realised she wasn’t vaccinated against that,” said her father, Lee Draper.
The Complexity of MenB Vaccination
Experts are divided on the issue of vaccinating teenagers against MenB due to the complex nature of the bacteria. Professor Sir Andrew Pollard of Oxford University highlights that MenB is not a single strain but rather a collection of various strains, some of which the existing vaccine cannot protect against. Additionally, while the MenB vaccine is effective for infants, its efficacy diminishes in older age groups.
Current guidelines suggest that while some individuals, particularly those with specific health conditions, are eligible for the MenB vaccine via the NHS, the general teenage population is not included. This decision is rooted in the vaccine’s cost-effectiveness and its limited long-term protection. In the event of an outbreak, immediate solutions such as antibiotic prophylaxis are prioritised over vaccination, which requires time to develop immunity.
Public Awareness and Action
The outbreak in Kent has sparked a surge in demand for MenB vaccinations, particularly in pharmacies, where stock is quickly depleting. Health authorities are urging the public, especially students in the affected areas, to remain vigilant about the symptoms of meningitis and to seek medical assistance promptly.
Dr Gayatri Amirthalingam from the UKHSA has reassured the public that, while the situation in Kent is serious, there is currently no evidence of a wider epidemic. Nonetheless, she emphasised the importance of staying informed about vaccinations and recognising the symptoms of meningococcal disease, which can develop rapidly.
Why it Matters
The ongoing outbreak of meningitis B in Kent underscores a critical public health issue: the need for comprehensive vaccination strategies that adapt to emerging risks. The tragic experiences of families affected by the disease serve as a stark reminder of the vulnerabilities faced by young people in the absence of adequate protection. As discussions surrounding the MenB vaccine evolve, it is imperative that health authorities not only address the immediate outbreak but also consider long-term solutions to enhance the resilience of the population against this preventable yet deadly disease.
